By admin 
The landscape of American preventative medicine is on the verge of a significant shift as federal regulators move to address the financial barriers that have long hindered effective tobacco cessation and substance misuse interventions. In a move widely praised by public health advocates, the Centers for Medicare and Medicaid Services (CMS) has proposed a substantial 19% increase in reimbursement rates for physicians who provide counseling to help patients quit smoking or address alcohol and substance misuse. This adjustment, tucked within a massive 1,592-page document outlining proposed changes to Medicare’s physician fee schedules, represents a strategic attempt to align financial incentives with the clinical effort required to treat the nation’s leading causes of preventable death.
Tobacco use remains the primary driver of avoidable mortality in the United States, contributing to nearly half a million deaths annually and hundreds of billions of dollars in healthcare costs. Despite the well-documented benefits of quitting, the clinical reality for most primary care physicians has been one of restricted time and inadequate compensation. For years, the standard reimbursement for tobacco cessation counseling hovered around a meager $10 per session—an amount that many providers argue fails to account for the complexity of behavioral change or the time required to develop a comprehensive cessation plan. The new proposal aims to rectify this by "more accurately reflecting the clinical intensity and work associated with these time-based services," according to the CMS document.
The implications of this policy change extend far beyond the Medicare population. While Medicare and Medicaid currently provide health coverage for approximately two in five Americans, their influence on the broader healthcare market is even more profound. Private insurance companies historically look to Medicare’s fee schedules as the benchmark for their own reimbursement models. Consequently, a nearly 20% bump in federal rates is expected to trigger a ripple effect across the entire private sector, potentially making tobacco and substance misuse counseling a more viable and prioritized service in clinics nationwide.
Ned Sharpless, a former director of the National Cancer Institute and current professor of cancer policy and innovation at the University of North Carolina School of Medicine, has spent years advocating for such a change. Having worked with both the Biden and Trump administrations to emphasize the importance of cessation services, Sharpless views the proposal as a long-overdue victory for preventative health. "We have something to offer these patients," Sharpless noted, highlighting that while the increase won’t make physicians wealthy, it elevates the status of counseling from an "afterthought" to a service on par with other essential medical activities.
The necessity of this intervention is underscored by the stark disparity between those who want to quit smoking and those who successfully do so. Statistics from the Centers for Disease Control and Prevention (CDC) indicate that while the majority of smokers express a desire to quit, the success rate for those attempting to do so without professional assistance is less than 10%. However, clinical research consistently shows that these odds improve dramatically when patients receive a "gold standard" of care: a combination of behavioral counseling and FDA-approved pharmacotherapy.
Treatments such as varenicline (formerly marketed as Chantix), nicotine replacement therapies like patches and gums, and bupropion have proven effective in mitigating the physical symptoms of withdrawal and reducing cravings. Yet, the delivery of these treatments remains alarmingly low. According to 2022 CDC data, only 5% of individuals who recently attempted to quit smoking received both counseling and medication. The current system, characterized by low reimbursement and high patient volume, often results in what experts call "drive-by counseling," where a doctor might simply tell a patient "you should quit" without providing the tools or follow-up necessary to achieve that goal.
Adam Goldstein, a professor and director of tobacco intervention programs at the UNC School of Medicine, emphasizes that effective cessation requires a structured, evidence-based approach. This includes discussing a patient’s specific motivations, identifying environmental triggers, and establishing a clear medication protocol. Ideally, this would involve frequent follow-ups, a task that is often impractical for overstretched primary care physicians. Goldstein and Sharpless have both pointed toward the "diabetes educator" model as a potential solution. In this framework, specialized tobacco treatment specialists—much like those who help patients manage chronic conditions like diabetes—would be integrated into clinical practices and reimbursed by Medicare to provide the intensive support patients need.
The proposed 19% increase also applies to interventions for alcohol and substance misuse, areas of public health that have seen escalating crises in recent years. Alcohol-related deaths have surged, yet screening and brief intervention (SBI) remains an underutilized tool in the clinical setting. A study cited by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) found that while 70% of patients with alcohol use disorder were asked about their drinking habits, only 12% received a brief intervention, and a mere 5% were referred to specialized treatment.
The barriers to addressing alcohol misuse are multifaceted, involving not just low reimbursement but also the social stigma associated with the disorder and a lack of training among general practitioners. Tim Clement, vice president of federal government affairs at Mental Health America, noted that while the pay bump is a "good thing" and a necessary step, it may not be a panacea. He suggested that other systemic issues, such as the shortage of mental health professionals and the lack of integrated behavioral health services in primary care, continue to play a role in the limited uptake of these services.
For the proposed changes to have a transformative impact, many experts argue they must be paired with broader structural reforms within the healthcare system. Adam Goldstein suggested that the reimbursement hike should be the catalyst for implementing "reliable tobacco-use screening, electronic-health-record prompts, standing medication protocols, and robust quitline referral systems." Without these supporting structures, the financial incentive alone may not be enough to change the ingrained habits of busy medical practices.
The public has until September 14 to submit comments on the proposal, after which CMS will review the feedback before finalizing the physician fee schedule for the upcoming year. If finalized, the change would represent one of the most significant federal investments in behavioral health counseling in recent memory.
Anne DiGiulio, the American Lung Association’s senior director of nationwide tobacco cessation and health policy, described the prioritization of cessation as a service that is "long overdue." The sentiment is echoed by many in the oncology and cardiology communities, who see the direct results of tobacco and alcohol misuse in the form of late-stage cancers and heart disease. By shifting the focus toward prevention through incentivized counseling, the healthcare system may finally begin to address the root causes of these chronic conditions rather than just treating the symptoms.
The economic argument for the increase is as compelling as the clinical one. Tobacco-related illnesses cost the U.S. healthcare system more than $240 billion annually in direct medical care. By investing a relatively small amount in increased reimbursement for counseling, the federal government stands to save billions in the long term by reducing the incidence of stroke, lung cancer, and chronic obstructive pulmonary disease (COPD).
As the deadline for public comment approaches, the healthcare industry is watching closely. For advocates like Ned Sharpless, the proposal is more than just a line item in a regulatory document; it is a validation of years of research and advocacy. "Every once in a while," Sharpless remarked, "it’s good to have a good story." In an era of complex healthcare challenges, the move to empower doctors to help their patients quit smoking and manage substance use is being hailed as a rare, straightforward win for American public health.
The success of this initiative will ultimately be measured not just in the number of doctors who bill for these services, but in the number of lives extended and the reduction in the heavy burden that preventable addiction places on families and the national economy. With Medicare leading the way, the path toward a more preventative and supportive healthcare model seems clearer than it has been in decades.
